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Objective: The coronavirus disease 2019 (COVID-19) pandemic disrupted
healthcare delivery, including prenatal care. The study objective was to
assess if timing of routine prenatal testing changed during the COVID-19
pandemic.
Methods: Retrospective observational cohort study using claims data from a
regional insurer (Highmark) and electronic health record data from two
academic health systems (Penn Medicine and Yale New Haven) to compare
prenatal testing timing in the pre-pandemic (03/10/2018–12/31/2018 and
03/10/2019–12/31/2019) and early COVID-19 pandemic (03/10/2020–12/31/
2020) periods. Primary outcomes were second trimester fetal anatomy
ultrasounds and gestational diabetes (GDM) testing. A secondary analysis
examined ﬁrst trimester ultrasounds.
Results: The three datasets included 31,474 pregnant patients. Mean
gestational age for second trimester anatomy ultrasounds increased from the
pre-pandemic to COVID-19 period (Highmark 19.4 vs. 19.6 weeks; Penn:
20.1 vs. 20.4 weeks; Yale: 18.8 vs. 19.2 weeks, all p < 0.001). There was a
detectable decrease in the proportion of patients who completed the
anatomy survey <20 weeks’ gestation across datasets, which did not persist
at <23 weeks’ gestation. There were no consistent changes in timing of GDM
screening. There were signiﬁcant reductions in the proportion of patients
with ﬁrst trimester ultrasounds in the academic institutions (Penn: 57.7% vs.
40.6% and Yale: 78.7% vs. 65.5%, both p < 0.001) but not Highmark. Findings
were similar with multivariable adjustment.
Conclusion: While some prenatal testing happened later in pregnancy during
the pandemic, pregnant patients continued to receive appropriately timed
testing. Despite disruptions in care delivery, prenatal screening remained a
priority for patients and providers during the COVID-19 pandemic.
KEYWORDS

pregnancy, prenatal care, ultrasound, glucose tolerance test, gestational diabetes,
access to care, COVID-19
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to compare prenatal screening during the COVID-19
pandemic (03/10/2020–12/31/2020) with the pre-pandemic
period (matched months in the two years prior; 03/10/2018–
12/31/2018 and 03/10/2019–12/31/2019). This study was
approved by the Children’s Hospital of Philadelphia,
University of Pennsylvania, and Yale University Institutional
Review Boards.
Given the geographic, socioeconomic, and racial and ethnic
differences in SARS-CoV-2 infection, hospitalizations, and
deaths, analyses utilized data from three different and
complementary sources to increase study generalizability (10–
13). Insurer data came from Highmark, an independent
licensee of the Blue Cross Blue Shield Association, that
provided insurance coverage to people living in all of Delaware,
southwestern Ohio (one county), across Pennsylvania (63 of 67
counties), and all of West Virginia during the study period.
These data have geographic variation across metropolitan and
non-metropolitan areas. The two health systems studied were
Penn Medicine and Yale New Haven Hospital. The Penn
Medicine health system serves the greater Philadelphia area,
which spans southeastern Pennsylvania and central New Jersey,
a major metropolitan region with racial, ethnic, and
socioeconomic diversity. The Yale New Haven Health system
provides care for the smaller metropolitan center of New
Haven and the surrounding areas of Connecticut whose
population composition is different than that in Philadelphia.
Pregnant patients included in the primary cohort, which
was created to examine primary outcomes (second trimester
testing), met al.l three of the following inclusion criteria: (1)
<14 weeks’ gestation by 03/10/2020 (last menstrual period 12/
04/2019–3/9/2020); (2) gave birth at ≥20 weeks’ gestation by
12/31/2020; and (3) singleton pregnancies. We used an
analytic dataset from Highmark that required ZIP code to be
non-missing. In order to capture appropriate prenatal care,
further inclusion criteria depended on the data source. In
those insured by Highmark, patients had to be enrolled in a
plan by before 14 weeks’ gestation. Patients at Penn Medicine
and Yale New Haven Health systems had to have initiated
prenatal care, either in-person or via telemedicine, before 28
weeks’ gestation. The analytic dataset was checked to ensure
that no pregnant patients were in both the Highmark and
Penn Medicine data. A secondary cohort of pregnant patients,
which was created to examine receipt of ﬁrst trimester
ultrasound, included pregnant patients who were <5 weeks’
gestation by 03/10/2020 (last menstrual period 02/02/2020–
03/09/2020), and met the same birth and prenatal care
initiation criteria as the primary cohort.

Introduction
The coronavirus disease 2019 (COVID-19) pandemic
created many disruptions in healthcare delivery, including
obstetric care. Changes to obstetric care delivery were made
quickly to decrease the risk of virus transmission across
inpatient and outpatient settings (1, 2). Health systems and
clinics responded by transitioning to or increasing virtual
visits and adopting reduced visit schedules (3, 4). However,
some aspects of prenatal care are not amenable to virtual care
encounters. Essential services, such as the obstetric ultrasound
to assess fetal anatomy and gestational diabetes screening,
require in-person interactions (5, 6). The ability of health
systems to provide, and pregnant patients to access these
essential, in-person obstetric services in a timely manner
during the COVID-19 pandemic is unclear.
To date, much of the literature regarding restructuring
prenatal care in the setting of the COVID-19 pandemic has
focused on telehealth visits and tailoring prenatal care schedules
based on a pregnant patient’s risk proﬁle (7, 8). Studies have
reported efforts to align in-person visits with essential obstetric
testing, yet the frequency with which such testing was completed
during the height of the pandemic is rarely described (3). There
are also reports of combining ultrasound-based tests (e.g., ﬁrst
trimester dating ultrasound with an ultrasound to measure
nuchal translucency) and examining completion of third
trimester testing for HIV, syphilis, and routine urine collection
as a marker of the adequacy of prenatal care (2, 9). Yet, despite
the importance of second trimester testing in the ongoing
management of a pregnancy and associated implications for the
infant, from identiﬁcation of birth defects to glucose monitoring
after birth, the frequency and timing of such testing during the
pandemic remains unknown.
The objective of this study was to assess if the timing of
essential prenatal testing changed between the pre-pandemic
and the early COVID-19 pandemic periods. We examined two
second trimester services as primary outcomes the timing of
(1) ultrasound for fetal anatomy and (2) gestational diabetes
screening with a glucose tolerance test (GTT) or glucose
challenge test (GCT). We examined receipt of ﬁrst trimester
ultrasound as a secondary outcome. Given the disruption and
strain the COVID-19 pandemic created in the health care
system, we hypothesized that routine screening would happen
later in pregnancy during the COVID-19 pandemic.

Methods
Study design and population

Study outcomes
This was a retrospective observational cohort study using
claims data from an insurer in the MidAtlantic and electronic
health record (EHR) data from two academic health systems
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“anatomy scan”, “full fetal survey”) and (2) glucose tolerance
testing (GTT) or glucose challenge testing (GCT) to screen
for gestational diabetes. The second trimester of pregnancy
included the period from 14 weeks and 0 days to 27 weeks
and 6 days. Timing was assessed by the number of completed
weeks’ gestation. In addition to timing, the proportion of
pregnant patients completing testing before 20 weeks’ given
potential implications for pregnancy management and by the
recommended time point before 23 weeks’ gestation for
second trimester ultrasound and before 29 weeks’ gestation
for GTT/GCT was assessed.
The second trimester ultrasound to assess fetal anatomy was
identiﬁed using current procedural terminology (CPT) codes
76805, 76810, 76811, 76812, 76813, 76815, and 76816 in the
Highmark data, EHR procedure names “Ultrasound complete”
and “US Preg 2nd/3rd tri” occurring at ≥14 weeks’ gestation in
the Penn Medicine data, and in the Yale New Haven data the
aforementioned CPT codes with the addition of 76801 and
76802 for ultrasounds speciﬁed as “complete”. If pregnant
patients had more than one ultrasound to fully assess fetal
anatomy, the ﬁrst ultrasound to assess fetal anatomy was used
to examine timing. The identiﬁcation of GTT/GCT screening
utilized CPT codes 82950, 82951, and 82952 in the Highmark
data, EHR procedure names “1 h glucose gestational 1 h”, “2 h
glucose tolerance - 2 h”, “2 h glucose tolerance 1 h”, “2 h glucose
tolerance fasting”, “3 h glucose gestational 1 h”, “3 h glucose
gestational 2 h”, “3 h glucose gestational 3 h”, “3 h glucose
gestational fasting”, “Fasting glucose in glucose tolerance”,
“Glucose tolerance test,$gestational,4spec(100 g)”, and “Glucose,
gestational screen (50 g)-140 cutoff” in the Penn Medicine data,
and all previously listed 1 and 3 h EHR procedure names in the
Yale New Haven data. This deﬁnition considered the ﬁrst GTT/
GCT completed during the second trimester and did not
differentiate between one-hour GCT or, two- or three-hour GTT.
The secondary outcome was receipt of ﬁrst trimester
ultrasound, which is routinely used to conﬁrm an intrauterine
pregnancy and provide an assessment of gestational age. This
was deﬁned as the ﬁrst ultrasound of any type in the three
data sources. The proportion of patients who completed a
ﬁrst trimester ultrasound before 14 weeks’ gestation (when
dating of a pregnancy is most accurate) was also examined.

insurance type (private or public) (15), pregnant patient ZIP
code of residence, nulliparity, smoking during pregnancy
[deﬁned in Highmark data using International Classiﬁcation
of Diseases (ICD-10) code O993 and current smoker, former
smoker, or never smoker in the EHR], obesity (identiﬁed in
the Highmark data using ICD-10 codes E660–E662, E664–
E669, Z683, Z684, and O9921 and a pre-pregnancy body
mass index ≥30 in the EHR data), pre-existing hypertension
(deﬁned in the Yale New Haven data with ICD-10 codes I10–
I16 or O10 and in the Penn data as these ICD-10 codes on
two or more occurrences at least 30 days apart), hypertensive
disorders of pregnancy, including gestational hypertension
(deﬁned in the Yale data with ICD-10 codes O12 and O13
and in the Penn data as these ICD-10 codes on two or more
occurrences at least one day apart), preeclampsia (deﬁned in
the Yale data with ICD-10 codes O11 and O14 and in the
Penn data as these ICD-10 codes on two or more occurrences
at least one day apart), Hemolysis, Elevated Liver enzymes
and Low Platelets (HELLP) (deﬁned using ICD-10 code
O142), and eclampsia (deﬁned using ICD-10 code O15), preexisting diabetes (deﬁned in the Yale data as ICD-10 codes
E08-E11, E13, O240, O241, and O243 and in the Penn data
these ICD-10 codes on two or more occurrences at least 30
days apart) (16), gestational diabetes (deﬁned in the Yale data
as ICD-10 code O244 and in the Penn data as this ICD-10
code on two or more occurrences at least one day apart) (17),
preterm birth (deﬁned as birth <37 weeks’ gestation), and
SARS-CoV-2 positivity during pregnancy. Race/ethnicity and
nulliparity variables were not available in the insurer data.
Patient ZIP code was not available in the Yale EHR data.

Statistical analysis
Characteristics of patients across the three datasets were
reviewed. Within each data source, bivariate analyses were
used to compare pregnant patient sociodemographic
characteristics and medical conditions in the pre-pandemic
and the early COVID-19 pandemic periods. The timing of
second trimester ultrasound to fully assess fetal anatomy,
GTT/GCT, and initial ﬁrst trimester ultrasound was similarly
compared between periods. Bivariate tests of association were
performed using χ 2 or Fisher exact test as appropriate for
categorical measures, and t-test or Wilcoxon for continuous
measures. Multivariable logistic regression models were used
to assess changes in testing timing between the two periods.
Speciﬁcally, changes in second trimester ultrasound to assess
fetal anatomy before 20 and 23 weeks’ gestation, GTT/GCT
before 29 weeks’ gestation, and the receipt of a ﬁrst trimester
United States were assessed. Model adjustment included the
following variables: maternal age, insurance type, obesity,
smoking, pre-existing hypertension and pre-gestational
diabetes. Pre-gestational diabetes was not included in models

Study variables
Pregnant patient and area-level sociodemographic
characteristics as well as pre-existing and pregnancy-associated
conditions were assessed, given associations with disparities
related to COVID-19 and potential risk factors for increased
prenatal testing. These characteristics included age (<20, 20–
<25, 25–<30, 30–<35, and ≥34 years) (14), race/ethnicity
(examined as Asian, Hispanic, Non-Hispanic Black, NonHispanic White, and Another, Unknown or Missing),
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assessing GTT/GCT timing. Analyses were completed using
SAS 9.4, Cary, NC.

TABLE 1 Patient characteristics in each of the three data sources.

Results

Total patients (n)

Data source

Penn
Medicine

Yale New
Haven

22,167

5,724

3,583

2018

7,954 (35.9%)

1,915 (33.5%)

1,227 (34.2%)

2019

7,404 (33.4%)

1,957 (34.2%)

1,192 (33.3%)

2020

6,809 (30.7%)

1,852 (32.4%)

1,164 (32.5%)

Birth year

Across the three data sources there were 31,474 pregnant
patients included. Of those, 22,167 (70.4%) were patients from
the Highmark cohort, 5,724 (18.2%) from the Penn Medicine
health system, and 3,583 (11.4%) from the Yale New Haven
health
system.
Pregnant
patient
sociodemographic
characteristics and medical conditions are reported in
Table 1. Pregnant patients in the Highmark data were
primarily privately insured (91.8%), the plurality of pregnant
patients in the Penn Medicine data were non-Hispanic Black
(41.3%), and the rates of smoking during pregnancy (7.3%)
and pre-existing hypertension (10.1%) were higher in the
pregnant patients from Yale New Haven. Patient
characteristics between the pre-pandemic and early COVID19 pandemic periods were compared within each dataset
(Supplementary Table S1). There were no consistent
differences in patient characteristics between periods across
the datasets.
The mean week of gestation for the initial second anatomy
scan was signiﬁcantly later in the COVID-19 period across all
three datasets (Highmark: pre-pandemic 19.4 weeks vs.
COVID-19 19.6 weeks p < 0.001; Penn Medicine: prepandemic 20.1 weeks vs. COVID-19 20.4 weeks p < 0.001;
Yale New Haven: pre-pandemic 18.8 weeks vs. COVID-19
19.2 weeks p < 0.001). Figure 1 (panel A) illustrates the
distribution of timing for completion of a second trimester
ultrasound for fetal anatomy. The proportion of patients who
completed second trimester ultrasound testing <20 weeks
during the COVID-19 pandemic period was lower in all three
datasets (Highmark: pre-pandemic 70.3% vs. COVID-19
64.2% p < 0.001; Penn Medicine: pre-pandemic 21.5% vs.
COVID-19 15.9% p < 0.001; Yale New Haven: pre-pandemic
82.5% vs. COVID-19 63.8% p < 0.001). In the adjusted
models, the odds of a second trimester ultrasound occurring
≥20 weeks’ gestation in the COVID-19 period was
signiﬁcantly higher in all three datasets (Table 2). By 23
weeks’ gestation, the proportion of pregnant patients who
completed second trimester ultrasound screening had
increased with no detectable difference in rates between prepandemic and COVID-19 periods across data sources
(Highmark: pre-pandemic: 96.5% vs. COVID-19 96.6% p =
0.95, Penn Medicine: pre-pandemic: 95.1% vs. COVID-19
93.9% p = 0.08, Yale New Haven: pre-pandemic: 96.7% vs.
COVID-19 95.8% p = 0.21), ﬁndings which were consistent in
the adjusted analysis (Table 2).
The mean week of gestation for which gestational diabetes
testing was completed was similar between periods in the
Highmark cohort and earlier in the academic institutions

Frontiers in Pediatrics

Highmark

Sociodemographic characteristics
Age (years)
<20

595 (2.7%)

106 (1.9%)

84 (2.3%)

20–<25

3,340 (15.1%)

674 (11.8%)

398 (11.1%)

25–<30

6,501 (29.3%)

1,278 (22.3%)

864 (24.1%)

30–<35

7,462 (33.7%)

2,071 (36.2%)

1,304 (36.4%)

≥35

4,269 (19.3%)

1,595 (27.8%)

933 (26.0%)

Race and Ethnicity

Unavailable

Hispanic

Unavailable

422 (7.4%)

775 (21.6%)

Non-Hispanic Asian

Unavailable

441 (7.7%)

199 (5.6%)

Non-Hispanic Black

Unavailable

2,363 (41.3%)

632 (17.6%)

Non-Hispanic White

Unavailable

2,220 (38.8%)

1,868 (52.1%)

Another/Unknown/Missing

Unavailable

278 (4.9%)

109 (3.0%)

20,351
(91.8%)

3,488 (60.9%)

2,179 (60.8%)

Unavailable

2,595 (45.3%)

1,484 (41.4%)

Private Insurance
Health characteristics
Nulliparous
Smoked during pregnancy

1,028 (4.6%)

174 (3.0%)

263 (7.3%)

Obesity (BMI ≥30 kg/m2)

4,929 (22.2%)

1,544 (27.0%)

1,014 (28.3%)

Pre-existing HTN
Any HDP
Gestational HTN

928 (4.2%)

332 (5.8%)

363 (10.1%)

2,628 (12.1%)

1,147 (20.0%)

742 (20.7%)

1,512 (6.8%)

741 (13.0%)

442 (12.3%)

Preeclampsia

964 (4.4%)

390 (6.8%)

269 (7.5%)

HELLP

64 (0.3%)

13 (0.2%)

14 (0.4%)

Eclampsia

88 (0.4%)

3 (0.1%)

17 (0.5%)

Preexisting diabetes

296 (1.3%)

129 (2.3%)

79 (2.3%)

Gestational diabetes

1,872 (8.4%)

424 (7.4%)

295 (8.6%)

Preterm birth (<37 weeks’
gestation)

1,893 (8.5%)

502 (8.8%)

274 (7.7%)

BMI, body mass index; HTN, hypertension; HDP, hypertensive disorder of
pregnancy; HELLP, Hemolysis, Elevated Liver enzymes and Low Platelets.
Hypertensive disorder of pregnancy includes gestational hypertension,
preeclampsia, HELLP, and eclampsia.

(Highmark: pre-pandemic 25.1 weeks vs. COVID-19 24.9
weeks p = 0.1; Penn Medicine: pre-pandemic 27.0 weeks vs.
COVID-19 26.4 weeks p < 0.001; Yale New Haven: prepandemic 24.2 weeks vs. COVID-19 23.6 weeks p = 0.01). The
distribution of timing of completion of gestational diabetes
testing by gestation age week is shown in Figure 1 (panel B),
for which there were no statistically signiﬁcant changes in
completion of timing before 29 weeks’ gestation in the
Highmark and Penn Medicine data (Highmark: pre-pandemic
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FIGURE 1

Distribution of completion of second trimester testing with an ultrasound to assess fetal anatomy (panel A) and gestational diabetes (panel B) across
the three data sources.

TABLE 2 Unadjusted and adjusted odds of second trimester prenatal testing timing during the COVID-19 pandemic period.

Prenatal test

Highmark
Odds ratio
(95% CI)

Penn Medicine

Yale New Haven

Adjusted odds
ratio (95% CI)

Odds ratio
(95% CI)

Adjusted odds
ratio (95% CI)

Odds ratio
(95% CI)

Adjusted odds
ratio (95% CI)

First 2nd trimester fetal anatomy 1.32 (1.24, 1.41)
ultrasound ≥20 weeks

1.33 (1.25, 1.41)

1.46 (1.25, 1.70)

1.46 (1.25, 1.71)

2.68 (2.28–3.14)

2.70 (2.29–3.17)

First 2nd trimester fetal anatomy 0.98 (0.84, 1.15)
ultrasound ≥23 weeks

1.04 (0.89, 1.22)

1.27 (0.99, 1.64)

1.27 (0.98, 1.65)

1.27 (0.88–1.83)

1.30 (0.89–1.88)

First GCT/GTT ≥29 weeks

1.00 (0.88, 1.12)

0.93 (0.80, 1.07)

0.91 (0.79, 1.06)

1.31 (1.03–1.66)

1.38 (1.08–1.76)

0.92 (0.82, 1.04)

All models reference the pre-pandemic period. GCT/GTT models reference testing between 20 and 29 completed weeks’ gestation.

14 weeks’ gestation) was unchanged during the COVID-19
pandemic period for patients captured in the Highmark
data (pre-pandemic 82.4% vs. 83.8%, p = 0.63), but
decreased signiﬁcantly among patients seen in the Penn
Medicine and Yale New Haven health systems (Penn
Medicine pre-pandemic 58.7% vs. COVID-19 41.0%, p =
<0.001; Yale New Haven 78.8% vs. COVID-19 66.8%, p =
<0.001). This ﬁnding in the academic institutions persisted
in adjusted analyses, as the COVID-19 period was
associated with higher odds of not completing a ﬁrst
trimester ultrasound (Penn Medicine: adjusted odds [aOR]
2.11, 95% conﬁdence interval [CI] 1.74, 2.56, Yale New
Haven: aOR 1.93, 95% CI 1.49, 2.51).

90.9% vs. COVID-19 91.5% p = 0.21, Penn Medicine: prepandemic 75.5% vs. COVID-19 76.5% p = 0.45) and a
decrease in the proportion of testing completed before 29
weeks’ gestation in the Yale New Haven data (pre-pandemic
87.8% vs. COVID-19 84.7% p = 0.03). These results were
consistent in the adjusted models (Table 2).
Across the three data sources there were a total of 6,310
pregnant patients in the secondary cohort who were
<5 weeks’ gestation by 03/10/2020 for which the secondary
outcome of ﬁrst trimester ultrasound was examined. The
distribution of timing for the initial ultrasound in the ﬁrst
trimester is shown in Figure 2. The proportion of pregnant
patients who completed a ﬁrst trimester ultrasound (before
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FIGURE 2

Distribution of completion of ﬁrst trimester ultrasound across the three data sources.

complicated pregnancies and at-risk fetuses identiﬁed during
second trimester ultrasound testing.
Our data regarding glucose tolerance testing was not
consistent across the data sources, with a detectable shift only
noted in the Yale New Haven data. This shift may reﬂect
changes in coordination of in-person appointments and
testing, which have been described in the literature at other
academic institutions who were working to streamline
appointments and decrease the number of contacts with the
healthcare system. However, the overall timely completion of
gestational diabetes testing likely reﬂects the dedication of
providers and patients to ensure the timeliness of this testing,
given the downstream effects on blood sugar management via
dietary changes and medication initiation, which has
implications for maternal, fetal, and neonatal wellbeing.
One of the more surprising ﬁndings was the change in
receipt of a ﬁrst trimester ultrasound, which was a prominent
ﬁnding in the two academic health systems studied, but not in
the Highmark data. It is important to consider potentially
contributing factors. One factor may be the differences in
sociodemographic characteristics between patients captured in
the different data sources, speciﬁcally insurance type. A much
higher percentage of the Highmark patients were privately
insured, a characteristic associated with utilization of obstetric
care and early initiation of prenatal care (19, 20). Another
explanation is that the capture of ﬁrst trimester ultrasounds is
more complete in the insurer data as it reﬂects billable
services outside of a single health system. In contrast, it is
plausible that patients in the Penn Medicine or Yale New
Haven cohorts were more likely to have their ﬁrst trimester
ultrasounds completed outside of these respective health
systems, especially during the peak of the pandemic if patients
perceived the burden of COVID-19 to be higher in tertiary
health systems. However, the low rates of ﬁrst trimester
ultrasounds are concerning. First trimester ultrasounds are
standardly used in conjunction with the last menstrual period
to determine the gestational age of a pregnancy. Without an
accurate last menstrual period or ﬁrst trimester ultrasound,
pregnancy dating is less accurate, which can have

Discussion
Although the average time at which second trimester
ultrasounds occurred during the early phase of the COVID19 pandemic was later in pregnancy, overall patients
continued to receive appropriate routine prenatal second
trimester ultrasounds and gestational diabetes testing.
However, in both academic institutions the rate of receipt
and adjusted odds of a ﬁrst trimester ultrasound was
signiﬁcantly lower during the COVID-19 period. While our
data demonstrate that prenatal testing during the second
trimester in the COVID-19 period continued to meet
guidelines from professional organizations, ﬁrst trimester, inperson services may have been deprioritized.
The Guidelines for Perinatal Care recommend completion
of an ultrasound to assess fetal anatomy between 18 and 22
weeks’ gestation (18). While our data demonstrate there was
no difference in the proportion of pregnant patients who
completed this testing in the recommended time frame
(before 23 weeks’ gestation), we did appreciate a shift in the
mean gestational week during which this testing occurred and
the proportion of scans completed before 20 weeks’ gestation.
The reason for this shift is likely multifactorial. First, prior to
the pandemic, there were baseline practice differences across
the three patient groups, with patients in the Yale New Haven
system often receiving a second trimester ultrasound for fetal
anatomy earlier in gestation than the other cohorts. Second,
the shift in timing seen across the three datasets likely reﬂects
systemic changes. For example, practices shifted scans to later
in gestation to avoid incomplete image acquisition which
requires additional in-person encounters increasing the risk of
COVID-19 exposure. However, while screening was still
completed as recommended, the shift in timing may have
implications for pregnancies in which abnormal fetal anatomy
is diagnosed. The detection of severe and potentially lifelimiting congenital anomalies may inﬂuence a patient’s
decision to end a pregnancy which is often very time
sensitive. Furthermore, associated diagnoses made during the
second trimester may affect ongoing monitoring of
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ramiﬁcations on pregnant patients and their infants both at the
limits of viability as well as management of pregnancies that
surpass their estimated due date. First trimester ultrasounds
allow for the conﬁrmation of an intrauterine pregnancy,
identiﬁcation of multiple gestation pregnancies, and diagnosis
of cesarean scar pregnancies and other abnormalities or
disorders that may affect the health of the pregnant patient,
viability of the pregnancy, and associated monitoring. A ﬁrst
trimester ultrasound is also often a component of aneuploidy
screening and may facilitate early diagnosis of severe
anomalies (e.g., acrania). Timely diagnosis of severe
pregnancy related abnormalities or complications and
congenital anomalies during the ﬁrst trimester is particularly
relevant and may be time-sensitive given evolving access to
abortion services in the United States.
This study has limitations. The three datasets did not have
all the same variables available. For example, race and
ethnicity and nulliparity were not available in the Highmark
data. Similarly, not all variables were captured in the same
way across the three datasets (i.e., use of CPT codes vs. EHR
procedure names). Though we worked to harmonize the data
as best as possible, these differences may contribute to
variability across cohorts (i.e., rates of hypertension). We
could not determine the reason for ﬁrst trimester ultrasounds
and could not differentiate between viability and dating
ultrasounds. While changes in prenatal testing may have
downstream effects on pregnant patients and their infants, we
could not capture other outcomes in this study, such as
changes in pregnancy monitoring or termination after
ultrasounds nor the details of GDM management for the
patient during pregnancy nor infant after birth. These and
other outcomes warrant examination in future studies.
This study also has important strengths. We leveraged three
different and complementary datasets to improve study
generalizability with the representation of different
populations living in different communities with varying
medical conditions. These three datasets capture several
practice patterns both within and between health systems and
across different payer-mix groups. Where we observed
consistency across datasets, ﬁndings are likely to be similar in
other health systems and patient populations as well.
In summary, while ultrasound-based testing in the ﬁrst two
trimesters was done later in gestation during the early phase of
the COVID-19 pandemic in 2020, recommended second
trimester testing was largely completed as indicated. The
changes in receipt of ﬁrst trimester testing, speciﬁcally ﬁrst
trimester ultrasound, may have potential downstream effects
on pregnant patients and warrants attention and further
study. Although the COVID-19 pandemic created a massive
stress on the health care system, prenatal health care delivery
was generally maintained thanks to the dedication and
resilience of providers and patients who continued to
prioritize second trimester testing.
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